|
Pardes Biosciences Inc (NASDAQ: PRDS) |
|
PRDS's Market share relative to its competitors, as of Q2 2023
As of Q2 2023 (Revenue in Millions of $)
Date modified: 2025-03-14T02:59:17+00:00
|
Select the Relationship:
|
|
Select the Category:
|
|
| COMPANY NAME |
REVENUES
12 Months Ending
Q2 2023 |
MARKET SHARE
12 Months
Q2 2023 |
MARKET SHARE
MRQ
Q2 2023 |
MARKET SHARE
A Quarter Before
Q1 2023 |
| Pardes Biosciences Inc |
0.00 |
0.00% |
0.00 % |
0.00 % |
| Moderna Inc |
3,236.00 |
0.60% |
0.69% |
1.33% |
| Biontech Se |
4,277.28 |
0.79% |
0.79% |
0.00% |
| Novavax inc |
682.16 |
0.13% |
0.06% |
0.06% |
| Gilead Sciences Inc |
28,754.00 |
5.29% |
5.37% |
5.38% |
| Vir Biotechnology Inc |
74.21 |
0.01% |
0.01% |
0.00% |
| Red Rock Resorts Inc |
1,939.01 |
0.36% |
0.35% |
0.33% |
| Eterna Therapeutics Inc |
0.60 |
0.00% |
0.00% |
0.00% |
| Siga Technologies Inc |
138.72 |
0.03% |
0.06% |
0.01% |
| Innovation Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cocrystal Pharma Inc |
2.01 |
0.00% |
0.00% |
0.00% |
| Altimmune Inc |
0.02 |
0.00% |
0.00% |
0.00% |
| Nanoviricides inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Regeneron Pharmaceuticals Inc |
14,202.00 |
2.61% |
2.69% |
2.65% |
| Assembly Biosciences Inc |
28.33 |
0.01% |
0.00% |
0.01% |
| Ampio Pharmaceuticals inc |
0.05 |
0.00% |
0.00% |
0.00% |
| Abeona Therapeutics Inc |
3.97 |
0.00% |
0.00% |
0.00% |
| Abivax Sa |
0.00 |
0.00% |
0.00% |
0.00% |
| Arcus Biosciences Inc |
258.00 |
0.05% |
0.02% |
0.03% |
| Fibrogen Inc |
180.01 |
0.03% |
0.03% |
0.04% |
| Alpine Immune Sciences Inc |
56.52 |
0.01% |
0.00% |
0.02% |
| Cumberland Pharmaceuticals Inc |
37.87 |
0.01% |
0.01% |
0.01% |
| Contrafect Corporation |
0.00 |
0.00% |
0.00% |
0.00% |
| Moonlake Immunotherapeutics |
0.00 |
0.00% |
0.00% |
0.00% |
| Lianbio |
0.00 |
0.00% |
0.00% |
0.00% |
| Matinas Biopharma Holdings Inc |
4.28 |
0.00% |
0.00% |
0.00% |
| Opko Health Inc |
713.14 |
0.13% |
0.13% |
0.12% |
| Emergent Biosolutions Inc |
1,043.60 |
0.19% |
0.14% |
0.21% |
| Organon and Co |
6,403.00 |
1.18% |
1.13% |
1.13% |
| Astrazeneca Plc |
45,811.00 |
8.43% |
8.43% |
0.00% |
| Sanofi |
49,599.72 |
9.12% |
9.12% |
0.00% |
| Novartis Ag |
46,660.00 |
8.58% |
8.58% |
0.00% |
| Dmk Pharmaceuticals Corporation |
3.53 |
0.00% |
0.00% |
0.00% |
| Innovation1 Biotech Inc |
0.08 |
0.00% |
0.00% |
0.00% |
| Actavia Life Sciences Inc |
0.12 |
0.00% |
0.00% |
0.00% |
| 180 Life Sciences Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| Tiziana Life Sciences Ltd |
0.00 |
0.00% |
0.00% |
0.00% |
| Viracta Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Hcw Biologics Inc |
3.21 |
0.00% |
0.00% |
0.00% |
| Renovorx Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Indaptus Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Iterum Therapeutics Plc |
14.32 |
0.00% |
0.00% |
0.00% |
| Esperion Therapeutics inc |
332.31 |
0.06% |
0.05% |
0.04% |
| Palatin Technologies Inc |
2.18 |
0.00% |
0.00% |
0.00% |
| Altamira Therapeutics Ltd |
0.31 |
0.00% |
0.00% |
0.00% |
| Leap Therapeutics Inc |
1.50 |
0.00% |
0.00% |
0.00% |
| Cellectar Biosciences inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Xenetic Biosciences Inc |
2.46 |
0.00% |
0.00% |
0.00% |
| Xbiotech Inc |
8.21 |
0.00% |
0.00% |
0.00% |
| Journey Medical Corp |
57.77 |
0.01% |
0.01% |
0.01% |
| Casi Pharmaceuticals inc |
30.17 |
0.01% |
0.01% |
0.01% |
| Mineralys Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Third Harmonic Bio Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Immunome Inc |
12.51 |
0.00% |
0.00% |
0.00% |
| Takeda Pharmaceutical Company Limited |
29,166.69 |
5.36% |
5.36% |
0.00% |
| An2 Therapeutics Inc |
1.35 |
0.00% |
0.00% |
0.00% |
| Structure Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Mirati Therapeutics Inc |
38.19 |
0.01% |
0.01% |
0.01% |
| Prometheus Biosciences Inc |
4.00 |
0.00% |
0.00% |
0.00% |
| Eli Lilly And Company |
45,042.70 |
8.28% |
9.61% |
8.16% |
| Johnson and Johnson |
88,821.00 |
16.34% |
15.99% |
16.03% |
| Merck and Co Inc |
64,168.00 |
11.80% |
11.09% |
11.88% |
| Bristol myers Squibb Company |
48,300.00 |
8.88% |
8.76% |
8.48% |
| Pfizer Inc |
63,627.00 |
11.70% |
12.61% |
12.63% |
| SUBTOTAL |
543,743.11 |
100% |
140,843.67 |
100% |
PRDS's Market share relative to its competitors, as of Q2 2023 within the Major Pharmaceutical Preparations Industry
As of Q2 2023
PRDS's Market share relative to its competitors, as of Q2 2023 within the Healthcare Sector
As of Q2 2023
Note: Market share is calculated based on total revenue. To get a more accurate picture of Pardes Biosciences Inc's market divisions, geographic dispersion, segments, products, and services, visit Pardes Biosciences Inc's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here. |
